GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Moderna

Pfizer

Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks. The post Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market appeared first on Investor's Business Daily.

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market

Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up appeared first on Investor's Business Daily.

Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up

GSK PLC (LSE:GSK, NYSE:GSK) is growing at a "robust" rate and showing increasing confidence in its HIV treatments, according to Jefferies analysts, though they cut their share price target due to long-term challenges and cost worries. Jefferies kept its 'hold' rating and suggested a 2022 price target of 1,575p, a 4% drop on original targets, but this still sits above its current price of 1,415p.

GSK growing optimistic on HIV but long term challenges remain - analyst

GSK plc (NYSE:GSK ) 41st Annual JPMorgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Deborah Waterhouse - CEO of ViiV, HIV business Iain MacKay - Chief Financial Officer Conference Call Participants James Gordon - JPMorgan James Gordon Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst.

GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference (Transcript)

AstraZeneca

The global pharma sector is expected to see clinical trial readouts that could potentially de-risk approximately US$74bn of peak sales in 2023, according to a research report from Credit Suisse, This is in comparison to US$102bn of readouts in 2022 and US$78bn in 2021, excluding COVID-19-related treatments. The report also found that a record proportion of the 2023 readouts, approximately 40%, will come from line extensions where a drug is already approved for use in a different disease setting.

GSK, AstraZeneca: Will the two UK drugs giants ride the US$74bn pharma wave or will they be left beached?

GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.

GSK Signs Deal to Develop Antibodies for Treating Cancer

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales SHANGHAI , Jan. 4, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a license agreement with GSK plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.

GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

BioNTech SE

Sanofi

Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.

3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023

Gilead Sciences

Immunocore Holdings

Syndax Pharmaceuticals

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

Bionano Genomics

iCAD

Madrigal Pharmaceuticals

Schrodinger 

Verona Pharma

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

United Continental Hlds

Ulta Beauty

United Therapeutics

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.

5 Momentum Stock Bargains Hunters Would Love Chasing

GSK is a rare undervalued stock in the frothy pharmaceutical sector. It's demonstrating strong operating performance and expects record sales for Shingrix this year.

GSK: Why I'm Picking Up This Undervalued Gem

Options traders are making big bets on the upside for healthcare, particularly in shares of  GSK plc GSK.

Options Trader Betting On GSK Stock Rising Heading Into 2023 - GSK (NYSE:GSK)

GSK PLC (LSE:GSK, NYSE:GSK) is moving its global headquarters back to central London in 2024 in a major boost for the West End economy relocating from its current base in Brentford where it has been since 2002. The 10 storey building (currently known as Earnshaw) is on the corner New Oxford Street and Earnshaw Street and is scheduled for completion next year.

GSK to move global headquarters back to central London

Wave Life Sciences

Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline GSK, -0.72% to develop oligonucleotide therapeutics.

Wave, GSK enter strategic collaboration

PHILADELPHIA--( BUSINESS WIRE )--GSK plc (LSE/NYSE:GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patients previously treated with an approved Janus kinase (JAK) inhibitor. Additionally, new analyses from MOMENTUM showed that TI response with momelotinib at week 24 was associated with overall survival. These data were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (10-13 December) in New Orleans.

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).

GSK & Others Get Relief as US Court Dismisses Zantac Litigation

GSK has had a target price increase to £17 from £15.50 from Citibank following the latest judicial ruling in the Zantac case in the US, but the pharma remains only a 'hold' even so. Following the ruling, Citi now expects a £5bn settlement compared with the £15bn settlement previously discounted.

GSK gets chunky Citi target upgrade after Zantac ruling

GSK PLC (LSE:GSK, NYSE:GSK) remained on the sell list at UBS despite the favourable Zantac ruling in the US today which it said “is clearly a positive development for the defendants.” But it pointed out its sell rating is not based on the Zantac litigation – it assumes no liability in its valuation.

GSK remains on sell list at UBS despite Zantac ruling

Pharmaceutical giants GSK PLC (LSE:GSK, NYSE:GSK) (GSK.L), Pfizer Inc (NYSE:PFE) (PFE.N), Sanofi SA (SASY.PA) and Boehringer Ingelheim received a boost today as a US court ruled that claims the heartburn drug Zantac caused cancer were not supported by scientific evidence. Broker UBS said the ruling in the multi-district litigation (MDL) by US district judge Robin Rosenberg removed around 2,000 cases that had been filed in the MDL but as there had been a time limit for cases to be brought, could affect 70,000 cases in total.

GSK soars on Zantac ruling but litigation process likely to be lengthy

Shares of pharmaceutical giants GSK PLC and Sanofi SA soared on Wednesday after what one analyst described as a “best-case scenario” Florida ruling that dismissed thousands of potential lawsuits over heartburn drug Zantac.

GSK and Sanofi shares surge after Florida ruling dismisses Zantac lawsuits in what one analyst describes as ‘best-case scenario'

Tens of thousands of lawsuits alleged that the heartburn treatment could cause cancer. Complaints are still active in state courts.

GSK, Sanofi Shares Jump After U.S. Judge Dismisses Zantac Lawsuit

Shares of GSK and Sanofi surged in early trading on Wednesday, following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.

GSK, Sanofi shares brighten as thousands of Zantac lawsuits are dismissed

Haleon PLC

On July 18, GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business, Haleon PLC ( HLN , Financial). By separating the slow but steady consumer health business from the higher risk-reward pharmaceutical business, the spinoff was expected to drive GSK's stock valuation multiples higher, allowing it to fund more drug development and acquisitions.

News for GlaxoSmithKline Stock (GSK)